SCHEMBL2179863

SCHEMBL2179863

CC(=O)c1c(OCCCl)c(OCCCc2ccccc2)c2oc(C)nc2c1Cl

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.36
CNR2 P34972 1/20 0.35
CA9 Q16790 1/20 0.35
PDE4D Q08499 1/20 0.35
DAGLA Q9Y4D2 1/20 0.35
KCNA3 P22001 1/20 0.34
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
FFAR1 O14842 1/20 0.33
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
ESR1 P03372 1/20 0.33
MAPT P10636 1/20 0.33
MAPK10 P53779 1/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12409137 0.86 MEN1 (0.45) KMT2AALDH1A1
SCHEMBL1541995 0.72 GRIN2D (0.39) PDE4DKCNA3LMNAALDH1A1
SCHEMBL2180635 0.69 KCNA3 (0.36) FAAHDAGLAKCNA3LMNATSHR
SCHEMBL2180079 0.68 KCNA3 (0.42) PDE4DDAGLAKCNA3MTNR1B
SCHEMBL3757808 0.67 PDE4D (0.45) PDE4DKCNA3
SCHEMBL2180941 0.67 KCNA2 (0.46) DAGLAKCNA3
SCHEMBL3763110 0.67 PDE4D (0.43) PDE4DKCNA3LMNATSHRFFAR1
SCHEMBL3613546 0.66 KCNA3 (0.52) KCNA3
SCHEMBL14221359 0.65 KCNA3 (0.51) KCNA3
SCHEMBL3608600 0.65 KCNA3 (0.51) KCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507539-B2 Potassium channel blockers and uses thereof BIONOMICS LIMITED (AU) 2013-08-13 US disclosed
US-8507539-B2 Potassium channel blockers and uses thereof BIONOMICS LIMITED (AU) 2013-08-13 US disclosed
US-8507539-B2 Potassium channel blockers and uses thereof BIONOMICS LIMITED (AU) 2013-08-13 US disclosed
US-20110166130-A1 NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF BIONOMICS LIMITED (AU) 2011-07-07 US disclosed
US-20110166130-A1 NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF BIONOMICS LIMITED (AU) 2011-07-07 US disclosed
US-20110166130-A1 NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF BIONOMICS LIMITED (AU) 2011-07-07 US disclosed
WO-2009149508-A1 NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF BIONOMICS LIMITED (AU) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166130-A1 NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF KCNA3, KCNB1, KCNK3 FAAH 1861/4885CNR2 813/4885CA9 3945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.